What’s Going On With Rivian Stock?

Rivian Automotive Inc (NASDAQ: RIVN) shares are trading lower by 12.7% to $16.82 over the trailing five sessions, though marginally higher Monday morning.

Rivian Automotive Inc (NASDAQ:RIVN) shares are trading lower by 12.7% to $16.82 over the trailing five sessions, though marginally higher Monday morning. The stock has experienced a recent decline amid weakness in the EV industry, influenced by Tesla Inc’s disappointing third-quarter financial results.

Additionally, the rise in Treasury yields has negatively affected growth stocks, contributing to Rivian’s 20% drop in October. This decline was further exacerbated by the pricing of $1.5 billion in green convertible senior notes offerings by Rivian.

Understanding Rivian’s October Weakness

Rivian’s recent convertible senior notes issuance has raised concerns among investors due to the increased debt load. This added debt might hinder the company’s ability to fulfill financial obligations, potentially affecting its creditworthiness, leading to higher interest costs and potentially reducing profitability.

See Also: Oil & Gas Giant Chevron Agrees To Acquire Hess Corp At A Premium

What Investors Should Know

Rivian is offering senior, unsecured notes with a 3.625% annual interest rate, making semi-annual payments from 2024 and maturing on October 15, 2030. They are convertible under specific conditions before July 15, 2030, or later at the discretion of noteholders.

The conversion offers cash, Rivian common stock, or a combination at an initial rate of 42.9290 shares per $1,000 note principal, equivalent to $23.29 per share, providing a 27.5% premium over the stock price on October 5. The conversion rate may be adjusted due to certain events.

The proceeds will be used for environmentally friendly projects in line with the Green Bond Principles of 2021.

According to data from Benzinga Pro, Rivian has a 52-week high of $36.45 and a 52-week low of $11.68.

Total
0
Shares
Related Posts
Read More

Scilex Holding Company Releases Preliminary Unaudited Financial Results For Gross And Net Sales For The Year Ended December 31, 2023; Total Product Gross Sales Were In The Range Of $150M-$155M; Total Product Net Sales Were In The Range Of $46.5M-$52.5M

Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute

SCLX